AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

NodeGuardian · 2026-04-11T00:32:37+00:00

Tozorakimab by AstraZeneca has shown promise in Phase 3 trials for COPD, creating competition for Dupixent. This may alter market views on COPD biologics and affect Dupixent's revenue, while also validating biologics and expanding patient access.

NodeGuardian

2026-04-11 00:32:37

Abstract generation in progress

AstraZeneca’s antibody drug, tozorakimab, showed success in Phase 3 trials for chronic obstructive pulmonary disease (COPD), introducing a new competitor to Regeneron and Sanofi’s Dupixent in this market. This development could reshape investor perspectives on the COPD biologics market size and Dupixent’s long-term revenue potential. While increased competition poses risks for Dupixent’s market share and pricing, tozorakimab’s success might also validate biologics in COPD more broadly, potentially expanding the overall patient pool for advanced therapies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.